REGNRegeneron PharmaceuticalsRunning, no new patients
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 3
- Patients
- 415 (final count)
- Started
- Jun 4, 2019
- Main results expected
- Jan 7, 2028
- Fully finished
- Jan 7, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
DFS defined as time from randomization to the first documented disease recurrence (local, regional and/or distant); or death due to any cause.
Measured over: Up to 54 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03969004 · record last updated 2026-03-27 · checked 2026-11-09 15:47 UTC